Acromegaly: Clinical Trials

19 completed, 4 terminated, 2 unknown, 1 recruiting. 27 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	27	Completed 19, Terminated 4, Unknown 2, Recruiting 1, Withdrawn 1
Phase 1	1	Completed 1
Phase 3	1	Completed 1

Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly	Phase 2	Recruiting	Marea Therapeutics	72	2026-07-23	2026-09-11
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly	Phase 2	Terminated	Alexion Pharmaceuticals, Inc.	8	2025-10-28	2026-08-07
A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly SYHX2008, Sandostatin LAR - Acromegaly	Phase 2	Completed	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	78	2024-04-16	2026-09-11
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly GHR-LRX - Acromegaly	Phase 2	Completed	Ionis Pharmaceuticals, Inc.	34	2021-01-04	2024-10-03
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) Paltusotine - Acromegaly	Phase 2	Terminated	Crinetics Pharmaceuticals Inc.	43	2020-01-29	2026-07-29
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL) - Acromegaly	Phase 2	Completed	Ionis Pharmaceuticals, Inc.	39	2019-07-25	2023-03-22
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Paltusotine - Acromegaly	Phase 2	Completed	Crinetics Pharmaceuticals Inc.	47	2019-03-12	2025-02-17
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Paltusotine, Placebo - Acromegaly	Phase 2	Completed	Crinetics Pharmaceuticals Inc.	13	2019-03-11	2025-03-17
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS-GHR-LRx, Placebo - Acromegaly	Phase 2	Completed	Ionis Pharmaceuticals, Inc.	43	2018-09-13	2022-11-14
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly BIM23B065 - Acromegaly	Phase 2	Terminated	Ipsen	4	2017-01-26	2019-03-08
Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy Tadalafil - Acromegaly Cardiomyopathy	Phase 2	Completed	Andrea M. Isidori	15	2016-07-01	2023-05-12
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly	Phase 1 / Phase 2	Completed	Ipsen	28	2015-03-01	2019-04-25
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) octreotide FluidCrystal® injection depot - Acromegaly, Neuroendocrine Tumors	Phase 2	Completed	Camurus AB	12	2015-01-01	2017-12-15
Phase II Study With ITF2984 in Acromegalic Patients Octreotide, ITF2984 500 mcg, ITF2984 1000 mcg - Acromegaly	Phase 2	Completed	Italfarmaco	48	2014-04-01	2016-06-16
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics saline, DG3173, octreotide - Acromegaly	Phase 2	Completed	Aspireo Pharmaceuticals Limited	8	2013-11-01	2018-02-15
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Pasireotide LAR - Acromegaly, Pituitary Gigantism	Phase 2	Completed	Novartis Pharmaceuticals	33	2012-10-16	2019-09-16
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. octreotide, DG3173 - Acromegaly	Phase 2	Completed	Aspireo Pharmaceuticals Limited	20	2012-10-01	2018-02-15
Clomiphene Citrate for Treatment of Acromegaly Clomiphene Citrate - Acromegaly	Phase 2	Completed	Felipe Henning Gaia Duarte	16	2011-01-01	2019-05-07
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly BIM 23A760 - Acromegaly	Phase 2	Terminated	Ipsen	109	2009-10-01	2019-11-22
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) lanreotide (Autogel formulation) - Acromegaly	Phase 2	Withdrawn	Ipsen		2008-05-01	2019-08-05

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Pituitary Neoplasms (2)  ·  Gigantism (1)  ·  Growth Disorders (1)  ·  Hypertrophy, Left Ventricular (1)  ·  Neuroendocrine Tumors (1)  ·  Serotonin Syndrome (1)

Broader conditions

Bone Diseases (27)  ·  Bone Diseases, Endocrine (27)  ·  Brain Diseases (27)  ·  Central Nervous System Diseases (27)  ·  Endocrine System Diseases (27)  ·  Hyperpituitarism (27)  ·  Hypothalamic Diseases (27)  ·  Musculoskeletal Diseases (27)  ·  Nervous System Diseases (27)  ·  Pituitary Diseases (27)  ·  Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Central Nervous System Neoplasms (2)  ·  Endocrine Gland Neoplasms (2)  ·  Hypothalamic Neoplasms (2)

Interventions

Octreotide (6)  ·  lanreotide (4)  ·  pasireotide (3)  ·  PTR 3173 (2)  ·  BIM23B065 (1)  ·  Clomiphene (1)  ·  Ethinyl Estradiol-Norgestrel Combination (1)  ·  Sodium Chloride (1)  ·  Somatostatin (1)  ·  TBR-760 (1)  ·  Tadalafil (1)

Sponsors

Ipsen (5)  ·  Crinetics Pharmaceuticals Inc. (3)  ·  Ionis Pharmaceuticals, Inc. (3)  ·  Novartis Pharmaceuticals (3)  ·  Aspireo Pharmaceuticals Limited (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Andrea M. Isidori (1)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)  ·  Camurus AB (1)  ·  Endo USA Inc., a Keenova Therapeutics Company (1)  ·  Felipe Henning Gaia Duarte (1)  ·  Italfarmaco (1)  ·  Marea Therapeutics (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Shanghai Jiao Tong University School of Medicine (1)

Countries

United States (13)  ·  Hungary (9)  ·  Italy (8)  ·  Poland (8)  ·  Serbia (8)  ·  Romania (7)  ·  France (6)  ·  Germany (6)  ·  Lithuania (6)  ·  Belgium (4)  ·  Brazil (4)  ·  Czechia (4)  ·  Netherlands (4)  ·  Russia (4)  ·  United Kingdom (4)

Top investigators

Elisa Giannetta, MD - Phd (1)  ·  Hai-jun Wang, MD (1)  ·  Marcello D Bronstein, MD, PhD (1)  ·  Marianne Pavel, Professor (1)  ·  Omar Serri, MD (1)  ·  Paolo Bettica, MD (1)

Results publications

PMID 36792844, PMID 19639415, PMID 20061334, PMID 20410233, PMID 21138567, PMID 23529827, PMID 30535537, PMID 32524605, PMID 34664531

NIH funding

2015 (2), 2018 (2), 2019 (2), 2004 (1), 2009 (1), 2014 (1), 2017 (1)